

GF/B45/EDP08 ***Approval of the Secretariat's Recommendation on Funding from the COVID-19 Response Mechanism (Ghana and Kenya)***

Approved on 20 July 2021

The Board:

1. Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism ("C19RM") awards exceeding US\$35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);
2. Approves the funding recommended for each country, as listed in Table 1 of GF/B44/ER07; and
3. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.

This decision does not raise new, material budgetary implications for operating expenses.

Table 1: Secretariat's Recommendation on Funding from C19RM¹

Please note that each country name is [linked](#) to the extranet site where relevant supporting documents are available for review.

Country/ Multicountry	Grant name	Currency	C19RM 2020 carry-over amount ²	Previously approved C19RM 2021 award ³	C19RM 2021 recommended amount for Board approval	Total C19RM 2021 funding	% of 2020-2022 allocation	Total C19RM 2021 funding plus C19RM 2020 carry-over	C19RM Unfunded Demand
Ghana	GHA-C-CHAG	US\$	235,770		2,717,392	56,674,028	25.00%	61,537,668	22,203,507
	GHA-C-MOH	US\$	3,846,919	17,641,249	27,072,881				
	GHA-H-WAPCAS	US\$	780,950		634,284				
	GHA-M-MOH	US\$	0		8,608,222				
Kenya	KEN-H-KRCS	US\$	4,978,504	6,229,652	10,543,147	102,271,604	24.63%	131,067,445	49,764,717
	KEN-H-TNT	US\$	5,093,996		6,915,191				
	KEN-M-AMREF	US\$	2,435,652		3,792,053				
	KEN-M-TNT	US\$	45,454		838,952				
	KEN-T-AMREF	US\$	4,162,589	12,459,592	38,326,556				
	KEN-T-TNT	US\$	12,079,646	12,459,301	10,707,161				

¹ The C19RM Investment Committee recommends C19RM Full Funding Requests awards of more than US\$35 million to the Global Fund Board for approval. This amount, measured in aggregate per country, does not include any funding awarded through the C19RM Fast-track process or through C19RM in 2020. The C19RM Investment Committee may also recommend awards under US\$35 million to the Global Fund Board for approval where it determines that the non-health product components of an award are of a nature and scale which raise significant concerns about risk and complexity.

² Estimated funds remaining from C19RM 2020 awards previously approved by the C19RM Investment Committee and carried over to this new award.

³ This includes Secretariat approved Fast-track and Full Funding awards, as well as awards previously approved by the Board.

